Gan to kagaku ryoho. Cancer & chemotherapy
-
Gan To Kagaku Ryoho · Aug 1999
Review[Present and future in brachytherapy--from the discovery of radium to the 21st century].
Brachytherapy can deliver high doses of radiation to a tumor with only low doses to the normal tissue. Brachytherapy can be classified as intracavitary, intraluminar and interstitial radiotherapy. It can be also divided into three groups according to dose rate: low (LDR), medium (MDR) and high (HDR) dose rates. ⋯ Brachytherapy has a long history of nearly 100 years. In recent years, the development of an HDR remotely controlled afterloading system and treatment planning system allows us to make a precise treatment plan and a uniform dose distribution. In the next century, HDR-brachytherapy will continue to play an important role in the field of radiotherapy.
-
Gan To Kagaku Ryoho · Aug 1999
Multicenter Study Clinical Trial[Clinical evaluation of granisetron (BRL43694) in nausea and vomiting induced by anticancer drugs--pediatrics].
Granisetron has been used widely for the prevention and treatment of nausea and vomiting associated with anticancer drugs in adult patients with cancer. This multi-center open study was conducted to study the efficacy, safety and usefulness of granisetron in children with cancer. ⋯ No serious adverse effects were observed. As granisetron 40 micrograms/kg had an excellent antiemetic effect and a high degree of safety against nausea and vomiting associated with anticancer drugs, it was shown to be useful for children with cancer.
-
Gan To Kagaku Ryoho · Aug 1999
Multicenter Study Clinical Trial[Clinical experiences of implantable vascular access device, "Vital Port" for arterial infusion chemotherapy].
We had the opportunity to use "Vital Port", a subcutaneous implantable vascular access port which was developed in the U. S. and has been used clinically in a multicenter study for clinical evaluation. To prevent the result from varying by facility, standardized criteria were made. ⋯ No complications were observed in any of the cases. Intra-arterial infusion chemotherapy was carried out without any problem. This port is lightweight and has good biocompatibility, and the clinical results were evaluated highly.